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Summary Hepatocyte growth factor (HGF/SF) is a potent renal proximal tubular cell (PTEC) mitogen involved in renal development. HGF/SF
is the functional ligand forthe c-metproto-oncogene, and germline c-metmutations are associated with familial papillary renal cell carcinoma.
Somatic von Hippel-Lindau disease tumour-suppressor gene (VHL) mutations are frequently detected in sporadic clear cell renal cell
carcinomas (RCC), and germline VHL mutations are the commonest cause of familial clear cell RCC. pVHL binds to the positive regulatory
components of the trimeric elongin (Slil) complex (elongins B and C) and has been observed to deregulate expression of the vascular
endothelial growth factor (VEGF) gene. HGF/SF has similarly been reported to up-regulate expression of the VEGF gene in non-renal
experimental systems. To investigate the mechanism of HGF/SF action in PTECs and, specifically, to examine potential interactions between
the HGF/c-met and the VHL-mediated pathways for renal tubular growth control, we have isolated untransformed PTECs from normal
kidneys, developed conditions for their culture in vitro and used these cells to investigate changes in mRNA levels of the VHL, elongin A, B
and C, VEGF, c-myc, c-fos and c-metgenes after HGF/SF exposure. Significant elevations in the mRNA levels of VEGF, c-myc, c-fos, c-met
and elongins A, B and C, but not VHL, were detected after HGF/SF stimulation of human PTECs (P< 0.02), with a consistent order of peak
levels observed over successive replicates (c-fos at 1 h, VEGF at 2-4 h, c-myc, at 4 h, followed by c-met and all three elongin subunits at
8 h). This study highlights the spectrum of changes in gene expression observed in PTECs after HGF/SF stimulation and has identified
possible candidate mediators of the HGF/SF-induced mitogenic response. Our evidence would suggest that the changes in PTEC VEGF
expression induced by HGF/SF are mediated by a VHL-independent pathway.
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Normal development requires precise control of gene expression
such that the balance between growth-promoting and growth-
suppressing influences is carefully co-ordinated. Aberrations in
these control systems may lead to abnormal organ development.
Perturbation of positive and negative control mechanisms for cell
growth and differentiation is a characteristic of cancer, and there
are many similarities between the processes involved in normal
development and tumorigenesis. Growth factors and oncogenes
implicated in normal renal growth and development include
hepatocyte growth factor/scatter factor (HGF/SF), its receptor
c-met and the c-myc transcription factor (Spencer and Groudine,
1991; Dressler and Douglass, 1992; Harris et al, 1993; Cantley et
al, 1994; Woolf et al, 1995). HGF/SF is a 97-kDa peptide growth
factor that, together with its high-affinity membrane receptor (the
c-met protooncogene product), appears to play an important role in
the early development of the metanephros and branching tubulo-
genesis ofthe developing kidney (Cantley et al, 1994; Woolfet al,
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1995). HGF/SF exerts powerful mitogenic effects on epithelial
cells, including renal proximal tubule cells (Harris et al, 1993),
having been shown in mice to prevent the onset of renal dysfunc-
tion and to stimulate DNA synthesis of renal tubular cells (renal
regeneration) after injury (Kawaida et al, 1994). Serum levels of
HGF/SF are rapidly induced after renal injury or failure (Chang et
al, 1996). HGF/SF is also believed to have a role in normal renal
development and is the most potent renal tubular cell mitogen
identified so far (Harris et al, 1993; Cantley et al, 1994; Woolf et
al, 1995). Precise details of how HGF/SF promotes renal tubular
cell mitogenesis are not known, although HGF/SF stimulation has
been reported to increase in vivo expression of the VEGF gene in
non-renal systems (Silvagno et al, 1995).
In adults, the most common form ofkidney tumour is clear cell
renal carcinoma, which arises from proximal tubular epithelial
cells (PTECs), with papillary RCC (the second most prevalent
RCC subtype) also thought to arise from these cells (Fleischmann
and Huntley, 1994; see below). Recently, germline mutations in
c-met have been reported in familial papillary RCC (Schmidt et al,
1997). Somatic mutations that inactivate the von Hippel-Lindau
disease tumour-supressor gene (VHL) are the most commonly
detected genetic event involved in the transformation of renal
tubular cells into clear cell RCC, but have not been observed in
papillary RCC (Latif et al, 1993; Foster et al, 1994; Gnarra et al,
1994; Herman et al, 1994; Shuin et al, 1994). Germline mutations
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in the VHL gene cause von Hippel-Lindau disease (VHL), which
is characterized by the development of clear cell renal cell carci-
noma (RCC), phaeochromocytoma and retinal, cerebellar and
spinal haemangioblastomas (Maher et al, 1990). Reintroduction of
the wild-type VHL gene into VHL-null RCC cells suppresses the
ability to form tumours in nude mice (Chen et al, 1995; Iliopoulos
et al, 1995). Although the VHL mRNA and protein are widely
expressed, analysis ofthe differential expression of VHL mRNA in
the kidney during human embryogenesis is compatible with a
specific role in normal renal development (Richards et al, 1996).
These findings suggest that the VHL gene would appear to be inti-
mately involved in the control of growth and differentiation of
normal renal tubular cells.
The precise mechanisms whereby the VHL gene negatively
regulates renal tubular cell growth are not clear, but the VHL
protein (pVHL) binds to the elongin B and C proteins (Kibel et al,
1995). These proteins (B andC, regulatory subunits) associate with
elongin A (functional subunit) to form a heterotrimeric transcrip-
tion elongation factor, elongin (SIll), which enhances RNA elon-
gation by suppressing RNA polymerase II pausing (Aso et al,
1995; Duan etal, 1995). Thus, in the presence ofpVHL, elongins B
and C aresequestered away fromelongin A, and thetranscriptional
activity of the elongin complex is reduced (Duan et al, 1995).
However, target genes regulated in this fashion bypVHL remain to
be identified, although expression levels of several genes are
known to be regulated at the level of transcript elongation. In
addition, pVHL appears to down-regulate expression of vascular
endothelial growth factor (VEGF), possibly by altering mRNA
stability (Gnarra etal, 1996; Iliopoulos etal, 1996; Siemeister etal,
1996). Recently, it has been suggested that the VHL/elongin B/C
complex may interact with otherproteins to regulate cell cycle exit
(Pause et al, 1997). Little is known about normal upstream control
of VHL gene expression, although the VHL promoter does contain
a binding site for the PAX 2 developmental transcription factor
(Kuzmin et al, 1995), which is specifically expressed during, and
required for, normal renal tubule development (Dressler and
Douglass, 1992; Gnarra and Dressler, 1995).
To investigate the mechanism of HGF/SF action and, specifi-
cally, to examine potential interactions between the HGF/c-met
and the VHL-mediated pathways for renal tubular growth control,
we have isolated untransformed PTECs from normal kidneys,
developed conditions for their culture in vitro and examined the
effect of HGF/SF stimulation of PTECs on mRNA expression of:
(1) VHL and related genes, such as elongin A, B and C and VEGF;
(2) the nuclear transcription factor c-myc, which is likely to be
relevant to renal tubule development because of its expression in
the developing kidney and its aberrant mRNA expression in clear
cell RCC (Yao et al, 1988; Spencer and Groudine, 1991) (c-myc is
of particular interest with respect to the VHL/elongin system
because of the reported regulation of its gene transcript levels
by transcriptional elongation (Spencer and Groudine, 1991) via
differential expression of P1 and P2 promoter-initiated tran-
scripts); (3) the c-met receptor proto-oncogene; and (4) the c-fos
nuclear transcription factor as a control early-response gene.
MATERIALS AND METHODS
Isolation and culture of normal renal tubule cells
Proximal tubule epithelial cells (PTEC) were isolated from the
cortex ofnormal human donorkidneys not used fortransplantation
because of technical reasons, using an adaptation of the methods
of Detrisac et al (1984). Cortical tissue was cut into approximately
1-mm cubes and subjected to collagenase digestion (60 mU ml-')
for 15-20 min; collagenase activity was then neutralized with fetal
calf serum (FCS), the resultant solution sieved through a 75-,um
filter mesh and the effluent centrifuged. The cell pellet obtained
was washed and plated out onto Petri dishes containing Dulbecco's
modified Eagle medium (DMEM)/F12 culture medium (volume
ratio 1:1) supplemented with selenium (5 jig ml-'), hydrocortisone
(36 jg ml-'), insulin (5 jg ml-'), triodothyronine (4 pg ml-'),
L-glutamine (4 x 106 M) and 2.5% FCS. After the first passage,
cells were transferred into a 75-ml culture flask and grown to 70%
confluence. Once confluence was achieved, the cell monolayers
obtained in the second to fourth subcultures were characterized
using various monoclonal antibodies (MAbs) directed against
cytokeratin and MAbs specific to proximal tubule brush border
enzymes, URO-3 (F23) and URO-4 (S27). A MAb against
membrane proteins specific to distal tubular cells URO-5 (T16)
was used as negative control. Desmin and Thy 1 antibodies were
used as negative controls to ensure that no contamination with
mesangial cells had occurred. All MAbs were commercially
obtained from Paisel &Lorray, Frankfurt, Germany. Asparathyroid
hormone (PTH) stimulus but not vasopressin exposure would
result in enhanced cyclic AMP (cAMP) production in PTEC cells,
a functional assay using parathyroid hormone (PTH)-sensitive
but vasopressin-insensitive cyclic AMP (cAMP) measurements
was also performed using the Amersham Biotrak cAMP [1251]
assay system (Amersham International, Little Chalford,
Buckinghamshire, UK) to further ensure that the cultured cells
obtained represented PTECs.
Stimulation of renal tubule mitogenesis with HGF/SF
PTECs from the third to sixth subpassage were grown to 70%
confluence, then serum starved for 72 h before stimulation with
HGF/SF. Initially, a series of dose-response experiments were
performed using a range of HGF/SF concentrations and an MTT
cell growth assay. Whereas exposure to 1 ng ml-' HGF/SF did not
cause any increase in cell growth compared with control cells,
exposure to a dose of 10 ng ml-' HGF/SF resulted in a mean 155%
increase in cell growth compared with unstimulated cells over
three independent determinations and was therefore selected for
use in all subsequent HGF/SF stimulations (data not shown).
For analyses of gene expression changes after HGF/SF stimula-
tion, proximal tubular cells were grown to 70% confluence, then
serum starved for 72 h before exposure to 10 ng ml-' HGF/SF.
Cells were harvested both before and after stimulation at given time
points (0, 1, 2, 4, 8, 24 h) and then stored at -70°C. Two indepen-
dentreplicate stimulations ofPTECs with HGF/SF were performed
for subsequent determination ofchanges in gene expression.
Determination of gene transcript levels
RNA extraction and reverse transcription
Total cellular RNA was extracted from harvested cell pellets
using Tri-reagent (Molecular Research Centre), its concentration
assessed spectrophotometrically (OD260nm) and stored at -70°C.
Four micrograms of total RNA was then reverse transcribed into
cDNA using an oligo d(T) primer (A3500 Reverse Transcription
System, Promega) and stored at -20°C. Both protocols were
performed according to the manufacturer's instructions.
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Table 1 Oligonucleotide primers and PCR amplification conditions
Gene Primer sequence Product length Annealing Magnesium chloride Original sequence
(F, forward; R, reverse) (bases amplified) temperature (°C) concentration (mM) Genbankaccession no.
Elongin A F 5'-AGGAGATGGAGGGGGACTAC-3' 231 bp (nt 349-579) 55 2 L47345
R 5'-AAGATGGAGGGGATTGAACA-3'
Elongin B F 5'-CCACCATCTTCACGGACGC-3' 282 bp (nt 35-316) 59 2 L42856
R 5'-GGGGCTTCATCACATCGG-3'
Elongin C F 5'-GCGGGACTGACGAGAAACTAC-3' 385 bp (nt 25-410) 54 2 L34587
R 5'-TTCGCAGCCATCAGCAGTT-3'
c-myc (P1 transcript) F 5'-CAGAGGCTTGGCGGGAAAAA-3' 586 bp (nt 116-701) 58 1.5 J00120 K01908 M23541
R 5'-GCTGCTGCTGGTAGAAGTTC-3' V00501 X00364
c-myc (Combined F 5'-ATTCCAGCGAGAGGCAGAGG-3' 498 bp (nt204-701) 58 2 See P1
P1 and P2 transcripts) R Use P1 reverse primer
c-met F 5'-CGCCGCTGACTTCTCCACTG-3' 481 bp (nt 143-624) 57 1.5 X54559
R 5'-TCGCTGGCAGGTCCCTCTGT-3'
Primerdesign
Pairs of oligonucleotide primers for polymerase chain reaction
(PCR) amplification of the c-met, c-myc P1, c-myc P1 + P2combined
(combined transcripts), and elongin A, B and C genes were
designed using the Oligo4 software package. To control against
contamination of cDNA results by genomic DNA, all pairs of
primers were designed to amplify adjacent exons that span an
intron. These primers and their optimal amplification conditions
are summarized in Table 1. Previously described primerpairs were
used for amplification of the P-actin (Horikoshi et al, 1992),
VEGF (detecting VEGF121 165 189ad206 isoforms; Wizigmann-Voos
et al, 1995), VHL and c-fos (Richards et al, 1996) genes. These
primers also distinguish between cDNA and genomic DNA prod-
ucts. The optimal amplification conditions for these genes were
(product size, annealing temperature, final magnesium chloride
concentration); P-actin (232 bp, 56°C, 1.5 mM), VEGF (452, 584,
656, 707 bp, 55°C, 2 mM), VHL (343 bp, 620C, 1.5 mM), c-fos
(452 bp, 62°C, 1.5 mM). The differentially sized cDNA and
genomic DNA products generated by each set of primers were
confirmed experimentally by PCR amplification and agarose gel
electrophoresis. Final magnesium chloride concentrations required
for the optimal PCR amplification of each gene were similarly
determined (data not shown).
Primerlabelling and PCR amplification conditions
Before PCR amplification, forward oligonucleotide primers were
32pradiolabelled attheir5'endusing T4 polynucleotide kinase. For
each labelling, the reaction mix comprised (50pl final volume)
l1.0gl of sterile distilled water, 25.0 jl of appropriate forward
primer (20gM stock), 10.0gl of 5 x polynucleotide kinase buffer
(MBI Fermentas), 2,1 of [y-32P]ATP (10 pCi 1-1; Amersham),
2 pl ofT4 polynucleotide kinase (15 U p1-1; MBI Fermentas). The
reaction mix was then incubated at 37°C for 30 min, followed by a
kinase inactivation step (70°C, 10min) and stored at -20°C before
use. Size markers (1 kb DNA ladder, Gibco BRL) were endlabelled
using identical conditions, with 1 ,ug of ladder used as the DNA
substrate in place ofthe oligonucleotide primer.
PCR reactions (final volume, 15 ,ul) were set up using the
following standard conditions: 8.9g1 ofsterile distilled water, 1.5 ,l
of 10 x PCR buffer [stocks containing 100 mM Tris-HCl (pH 8.8),
100 mm potassium chloride, 0.1% gelatin and magnesium chloride
concentrations in the range between 2.5 and 50 mM*], 1.2 g1 of
dNTP mix (containing 2.5 mm each dA, C, T, GTP), 0.8 p1 of 32p_
labelled forward primer* (10pM stock, from primer labelling
reaction), 0.4 p1 of reverse primer* -(20gM stock), 0.2g1 of Taq
polymerase (1 U pl-l stock, Super Taq, HT Biotechnology), 2 pl of
reverse transcription product. Individual PCR reactions were then
overlayed with mineral oil and amplified as follows: 5 min initial
denaturation stepat95°C, followedby therequirednumber* ofPCR
cycles of95°C, 1 min; x°C*, 1 min, 72°C, 1 min followed by a 10-
min final extension step at 72°C. *See sections headed Primer
design and Determination of gene transcript levels for individual
amplification conditions for each gene. The identity of each PCR
product was confirmed by direct sequencing (data not shown).
Determination ofgene transcriptlevels
The amount of PCR product produced for a given target gene is
only proportional to the gene transcript levels in the initial cDNA
stock at cycle numbers at which amplification remains exponential
(see Clifford et al, 1994). Preliminary experiments were therefore
performed to assess the PCR amplification kinetics of each target
gene in our samples, using samples from a preliminary time course
(data not shown). Amplification was found to be exponential for
all samples in the time course at 24 cycles for all genes analysed,
except elongin B (20 cycles) and0-actin (15 cycles). These condi-
tions were used in all subsequent analyses described, and ,-actin
amplification kinetics were checked in all subsequent replicate
time courses to confirm that these amplification conditions
remained unchanged.
The analysis of changes in gene transcript levels over each time
course studied was performed for each gene by the simultaneous
independent amplification ofcDNA from all six time points (and a
water blank control), using a commonly prepared reaction mix and
the previously defined conditions. Two microlitres of gel loading
buffer (stock containing 50% glycerol; 125 mM EDTA, pH 8.0;
0.1% sodium dodecyl sulphate (SDS); bromophemol blue/xylene
cyanol) was then added to each sample, and 5 pl of the mix sepa-
rated by ovemight electrophoresis (1.5 W, 12-18 h) on a 45 cm
long x 0.5 mm thick non-denaturing polyacrylamide gel in 0.5 x
TBE (4.5% acrylamide, 0.24% bis-acrylamide, 45 mM tris-borate,
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Figure 1 Autoradiographs showing examples of individual PCR-based analyses of changes in gene transcript levels over the time courses studied. Product
sizes and exposure times for each of the genes shown were: c-myc P1, 586 bp, 88 h; c-myc P1 + P2combined' 498 bp, 18 h; VEGF121 and 165' 452 bp and 584 bp,
18 h; VHL 343 bp, 12 h; Elongin C, 385 bp, 16 h; c-fos452 bp, 12 h; and 0-actin, 232 bp, 18 h
1 mM EDTA). PCRproduct sizes were confirmedby running 1 gl of
32p end-labelled DNA ladder (section headed Primer labelling and
PCR amplification condition) alongside the samples. Gels were then
dried at 80'C for 2 h under vacuum and exposed to radiographic
film (Kodak X-Omat LS). Exposure times were chosen for each
gene to allow visualization of the product bands without over-
exposure (saturation) of the film. Product band intensities were
quantified using a Lynx densitometer (Applied Imaging) and a
corresponding background density value subtracted for each band.
To standardize data between replicates, each individual corrected
band intensity was thenexpressed as apercentage ofthe mean inten-
sity of all six time points for that gene replicate. For each cDNA
sample, the PCR analysis ofeach gene was independently repeated
in triplicate and the three sets of results combined to give a mean
(± standard error) result for each time point. Transcript levels ofthe
target genes were then standardized relative to corresponding mean
(± standarderror) values fortheP-actin gene, which was included as
an intemal reference standard. Statistical comparisons between time
points were made using the InStat software package (GraphPad).
RESULTS
Changes in the gene transcript levels
For a given HGF/SF stimulation, gene and time point, the PCR-
based assay used to quantify changes in mRNA levels yielded
reproducible results overthree independent analyses, with standard
errors typically <10% ofthe mean value. No evidence ofthe conta-
mination ofcDNA results with genomic DNA was observed in any
replicate, and similarly no PCR products were observed in any of
the negative control reactions. Example autoradiographs from the
analyses performed are shown in Figure 1.
Vascularendothelialgrowth factor(VEGF)
The transcripts encoding the two secreted isoforms of VEGF
(VEGF121 and 165) were detected in all experiments, however both of
the intracellular isoforms (VEGF189 and206) were consistently unde-
tectable by our methods. Significant elevations in the expression
of both VEGF isoforms were observed in response to stimulation
with HGF/SF in both replicates (P < 0.0001, by AOV; see Figure
2E and F). In the first stimulation, rapid and equivalent increases
in gene transcript levels were observed for both isoforms from 0 h
reaching a peak at 4 h (>190% of TO levels), which was main-
tained through to 8 h after stimulation, transcript levels then fell
and approached starting levels by 24 h. Similar rapid elevations in
the expression ofboth sectreted VEGF isoforms were observed in
the second stimulation, however the peaks in expression levels
observed were less prolonged than in the first replicate, being
found at 2 h (130-150% of the TO value) and having fallen away
by the 4-h observation.
c-myc
c-myc gene transcript levels rose significantly after stimulation
with HGF/SF (P < 0.002, by AOV; see Figure 2G and H). Peak
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Figure 2 Changes in gene transcript levels after stimulation with HGF/SF for all genes analysed. Two independent replicate stimulations are shown (- -+- -,
replicate 1; - -U- _ -, replicate 2). Graphs show gene transcript levels (y-axis) plotted against time after stimulation in hours (x-axis). Transcript levels for each
gene are expressed as:
Target gene transcript levels (as % of mean levels) ± standard error (n = 3)
Corresponding /actin gene transcript levels (as % of mean levels) ± standard error (n = 3)
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in both replicates [P < 0.003 (Elongin A), P < 0.015 (Elongin B),
P < 0.001 (Elongin C); by AOV], with all three genes reaching
peak levels 8 h after stimulation in both replicates [170-180%
(Elongin A), 120-160% (Elongin B) and 120-150% (Elongin C)
of TO levels, then falling to approach starting levels by 24 h after
stimulation in all cases.
The ratio between Elongin A and VHL gene transcript levels at
each time point was calculated forboth time courses using the data
shown in Figure 2. The Elongin AIVHL ratio rose significantly in
both replicates (P < 0.0003, by AOV) to reach peak levels 4 h
(150% of TO levels, replicate 2) and 8 h (210% of TO levels, first
16 20 24 replicate) after stimulation (see Figure 3). The ratio then fell to
140% ofTO levels in the first replicate, but remained elevated at 8
and VHL gene transcript and 24 h (150% and 140% ofTO levels) in the second replicate. No
slations (- -t
- -, replicate consistent changes in the Elongin BIVHL, Elongin C/VHL, 3ing the data shown in
Elongin A/Elongin B and Elongin A/Elongin C ratios were
observed over the time courses of the two replicate stimulations
(data not shown).
levels of the P1 + P2combined transcript were reached 4 h post stimu-
lation (150-170% of TO levels) in both replicates, however, while
levels remained elevated through 8 h in the first, they had fallen
rapidly by 8 h in the second replicate. P1 + P2combined transcript
levels fell and approached starting levels by 24 h in both replicates
(see Figure 2G). The patterns ofchange observed for P1 transcripts
alone closely followed those reported for P1 + P2combined rising to a
peak between 4 h (replicate 2) and 8 h (replicate 1) afterstimulation
(at 120-130% ofTO levels), then falling to approach starting levels
within 24 h (see Figure 2H). No significant changes were observed
in the ratio between P1 and P1 + P2com.n transcript levels over the
entire time course in either replicate (P > 0.169, by AOV).
c-met
Transcript levels of the c-met gene rose significantly (P < 0.006,
by AOV) after stimulation with HGF/SF (see Figure 2I). Similar
changes in c-met expression were observed in both replicate
stimulations, with peak expression levels reached after 8 h in
both replicates (130-170% of TO levels), followed by a drop in
expression to levels approaching TO values by 24 h.
c-fos
Changes in c-fos mRNA levels were determined as a positive
control and rose rapidly and significantly (P < 0.002, by AOV) to
a peak level 1 h after stimulation with HGF/SF, then fell quickly to
reach levels similar to TO by 4-8 h (see Figure 2J). Similar trends
were observed in both replicates, although peak levels were more
pronounced in the second stimulation (350% vs 150% of respec-
tive TO values). c-fos mRNA levels were observed to rise signifi-
cantly again (P = 0.0019, by t-test) between 8 and 24 h in the first
stimulation, although no such change was found in the second
replicate.
The VHLlelongin system
In the first replicate stimulation, the variations observed in tran-
script levels of the VHL gene were not significant [P = 0.18, by
analysis of variance (AOV)]. The changes observed in the second
replicate were, however, just significant (P = 0.032, by AOV),
with peak levels observed at 8 h, 120% higher than those deter-
mined before stimulation (at TO) (see Figure 2D). Significant vari-
ations were observed in both replicates for the three elongin
subunits, all displaying closely similar patterns of change (see
Figure 2A-C). Elongin A, B and C mRNA levels rose significantly
DISCUSSION
In this present study, we have isolated normal proximal tubular
epithelial cells (PTECs) and developed conditions for their culture
in vitro. To examine the mechanisms ofaction ofHGF/SF-induced
mitogenesis, we first determined conditions at which renal tubular
cells can be stimulated to divide by exposure to HGF/SF. Changes
in the mRNA expression of the VHL gene and related genes (c-
myc, VEGF and elongin A, B and C) were then assessed during
HGF/SF-stimulated renal tubule mitogenesis. To our knowledge,
this is the first study to investigate possible associations between
HGF/SF renal mitogenesis and changes in the VHL/elongin
tumour-suppressor system. The nature of the changes induced
after growth factor exposure are undoubtedly complex and inter-
related, and the use ofnormal PTECs as our system of choice has
allowed us to observe the changes induced by HGF/SF stimulation
in untransformed cells carrying no genetic alterations. Our investi-
gations have confirmed the striking growth, differentiation and
morphological effects that HGF/SF exposure has on cultured
normal renal tubule cells, and has additionally yielded useful
initial information regarding the spectrum of transient changes in
gene expression induced during PTEC mitogenesis. Similar
patterns of change in expression were observed in both replicate
stimulations for each of the genes analysed. These have provided
good indications of the nature of the changes that occur in the
expression ofthese genes afterHGF/SF exposure. Specifically, the
genes overexpressed and the order in which they peak during the
time course studies are consistent over both replicates, with only
the c-myc and VEGF peak durations showing any real difference
between the two replicates. The observed differences have most
likely arisen from small variations in cell culture and stimulation
conditions. The degree of increase observed in both cell growth
(155% increase compared with untreated controls) and candidate
gene mRNA levels after HGF/SF exposure are entirely consistent
with the highly differentiated, untransformed nature of the PTECs
used which, unlike many tumour cell lines, do not display large
changes in their growth rate after growth factor exposure.
Furthermore, in view ofthe powerful mitogenic and morphogenic
effects of HGF/SF on PTECs (Cantly et al, 1994; Woolf et al,
1995), studies in which the observed changes in gene expression
are related to cell cycle, proliferative and morphogenic parameters
would be offurther interest.
BritishJournal ofCancer(1998) 77(9), 1420-1428 0 CancerResearch Campaign 19981426 SC Clifford etal
Because of the limited availability of untransformed PTECs
(-107 cells per timepoint), PCR-based analysis was selected as our
method of choice forevaluating changes in gene expression, so as
to maximize the amount of data obtainable from this limited
source. After careful preliminary validation of the PCR amplifica-
tion kinetics, our assay generated reproducible data over multiple
independent replicates. Closely similar patterns ofchanges in band
intensity were observed for each gene over the time course studied
in threeindependently performed analyses ofeach ofthe two repli-
cate stimulations, as evidencedby the small standard errors (<10%
ofmean) in the graphical representations of the data after densito-
metry. Whereas we were able to analyse changes in gene expres-
sion for several genes using multiple replicates, the available
sample material would only have yielded sufficient material for a
singleanalysis using more traditionaltechniques, such as Northern
blot hybridization. Finally, we note that the changes in expression
ofpositive control genes (such asc-fos, c-myc) observed in PTECs
after HGF/SF exposure using our assay were entirely compatible
with their defined roles as early-response genes in other experi-
mental systems.
This study provides the first evidence of changes in elongin
mRNA expression by exposure to growth factors. The concurrent
mRNA peaks of all three elongin (SIII) subunits at 8 h after
HGF/SF stimulation suggest that stimulation of transcriptional
elongation may enhance target gene expression after renal tubule
growth stimulation. In contrast to the elongins, VHL mRNA levels
did not vary significantly over the first stimulation time course
studied, and varied over a very narrow range in the second,
suggesting that VHL mRNA levels essentially remain invariant
before and after HGF/SF stimulation. Reports in the literature have
suggested that the Elongin A (positive regulation) and pVHL
(negative regulation) proteins compete for the binding of the
Elongin B and C subunits toregulatetranscriptional activity (Duan
et al, 1995). Furthermore, it has been reported that in vitro small
variations in the relative protein levels of Elongin A compared
withpVHL (between two- and fivefold) are sufficient to sequester
the B and C subunits away frompVHL. The increase observed in
the ratio between Elongin A and VHL mRNA levels (1.5- to 2.1-
fold) after HGF/SF stimulation might have significant effects on
transcriptionalelongation mechanisms ifthese mRNAchanges are
reflected in the relevantprotein levels. Thus, furtherinvestigations
regarding changes in VHL and elongin subunitprotein levels (and
post-translational effects) after HGF/SF exposure will be of great
interest when discriminatory antibodies to these proteins become
available. Further complexities are introduced by the potential
roles ofintracellularpVHLtrafficking andprotein phosphorylation
in controlling pVHL function (Lee et al, 1996; Stackhouse et al,
1996). In addition, there is circumstantial evidence that, in vivo,
VHL may not be a significant regulator oftranscriptional elonga-
tion, but that its major effect is through protein binding interac-
tions and cell cycle control (Pause et al, 1997). We did not find
evidence for profound changes in VHL mRNA levels after
HGF/SF exposure, and the recent identification ofgermline c-met
mutations inpatients with hereditarypapillary RCC (Schmidt et al,
1997), together with the absence of VHL gene mutations in
sporadic papillary RCC, suggests the presence of a non-VHL-
dependent pathway for HGF/c-met-stimulated proximal tubular
epithelial cell growth. We note thatup-regulation ofVEGF mRNA
levels is aconsequence ofboth VHL inactivation (a common event
in clear cell RCC) and stimulation of the HGF/SF-c-met axis (a
feature ofpapillary RCC) in renal cell systems.
In untransformed PTECs, c-fos mRNA levels reached peak
values within 1 h of exposure to HGF/SF as expected, followed by
peak c-myc mRNA levels between 4 and 8 h, consistent with their
reported roles as early-response genes aftergrowth factor exposure.
In other experimental systems, peak c-fos mRNA levels have
previously been demonstrated 30 min after HGF/SF exposure in
cultured epithelial cells (Boccaccio et al, 1994), and the induction
of c-myc mRNA levels has been similarly observed as an early
response to HGF/SF exposure in mouse epithelial cell lines
(Johnson et al, 1995). The c-myc gene can be expressed from four
promoters (P0, P1, P2, P3), all of which appear to be regulated
independently (Eick et al, 1990), with RNA initiated at the P2
promoter usually contributing 80-90% of total steady-state c-myc
RNA in normal cells (Spencer and Groudine, 1991). RNA pol II
pauses in the P2 promoterregion, causing premature attenuation of
P1 transcripts (Krumm et al, 1992), with the rate of RNA pol II
release from the P2 pause site shown to regulate c-myc transcrip-
tional activity (Strobl and Eick, 1992; Kohlhuber et al, 1993).
Thus, an enhanced rate of transcript elongation through the P2
pause site would be expected to result in a preferentially increased
number offull-length P1-initiated gene transcripts. In our PTECs,
equivalent changes in c-myc P1 and P1 + P2combined gene transcript
levels were observed in response to HGF/SF stimulation. In
normal cells and tissues, the ratio of P1/P2 initiated transcripts is
typically between 1:5 and 1:10 (Spencer and Groudine, 1991), and
thus P2-initiated transcripts should represent at least 80% of the
measured P1 + P2combined PCR product in normal PTECs. Thus, if
the increase in c-myc mRNA levels hadresulted from increased P1
transcript levels alone, an increase in the relative PI/PI +P2combine
ratio would have been expected over the time course, and this was
not the case. Likewise, if the enhanced c-myc mRNA levels had
resulted from P2 initiation alone, no increases in P1 transcript
levels would have been observed. Our data therefore suggest that
the enhanced c-myc mRNA levels observed afterHGF/SF stimula-
tion are mediated through both P1- and P2-initiated transcripts,
following closely similar patterns of change. Enhanced P2 tran-
script levels most likely arise through enhanced initiation, but the
increased P1 transcript levels may result fromchanges in transcript
elongation or enhanced initiation at the P1 promoter. The relation-
ship between changes in c-myc P1 expression and possible
HGF/SF-induced changes in the VHL-elongin system is
unknown, but such changes could not account for HGF/SF-
induced up-regulation ofc-myc expression.
VEGF is an endothelial cell-specific mitogen that induces
angiogenesis and vascular permeability in vivo (Connolly et al,
1989; Keck et al, 1989; Leung et al, 1989) and is commonly
up-regulated in sporadic RCC (Brown et al, 1993) as well as in
VHL-associated hereditary and sporadic haemangioblastomas
(Wizigmann-Voos et al, 1995). Thus, VEGF overexpression has
been hypothesized to play a role in determination of the vascu-
larity observed in VHL-associated tumours and the formation of
disease-associated cysts that may result from enhanced vascular
permeability. Four differentially spliced VEGF isoforms have
been described, the larger two of which are cell associated
(VEGF89 and VEGF206), while the smaller two are secreted
proteins (VEGF121 andVEGF165) (Ferrara et al, 1991; Breier et al,
1992). In PTECs, we observed increases in VEGF121 and 165 mRNA
levels peaking at 2-4 h after exposure to HGF/SF, while expres-
sion of the cell-associated (VEGF189 and 206) isoforms was not
detected. Enhanced VEGF mRNA levels may be induced by a
number of events, including growth factor stimulation, induction
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of hypoxia and oncogene activation (Finkenzeller et al, 1995;
Grugel et al, 1995; Ikeda et al, 1995; Rak et al, 1995). In addition,
Silvagno et al (1995) have reported that HGF/SF induces expres-
sion of angiogenic factors, including VEGF in vivo, and that a
neutralizing antibody to VEGF partly prevented HGF-induced
angiogenesis. Our results are consistent with these observations
and the concept that HGF/SF has a role in the control of renal
angiogenesis during development and that this role is, at least in
part, mediated through the induction ofVEGFexpression. As peak
elongin mRNA levels occur up to 6 h after the observed VEGF
peak, it seems unlikely that changes in VEGF expression result
from enhanced transcriptional elongation. Up-regulation ofVEGF
expression in response to growth factors, such as platelet-derived
growth factor, epidermal growth factor and tumour-promoting
agent (phorbol ester), results from promoter activation (Grugel et
al, 1995; Rak et al, 1995), whereas the VEGF response to hypoxia
appears to be primarily mediated at the mRNA stabilization level
(Finkenzeller et al, 1995; Ikeda et al, 1995). The pVHL-induced
changes in VEGF expression that have been demonstrated in vitro
appear to be mediated post-transcriptionally through mRNA stabi-
lization and not by influencing transcriptional elongation (Gnarra
et al, 1996; Iliopoulos et al, 1996).
Finally, our data support a role for the HGF/SF receptor (the c-
met proto-oncogene) as a delayed early-response gene in PTECs
(peak levels are reached at 8 h after stimulation). Similar results
have previously been described by Boccaccio et al (1994) in an
epithelial lung adenocarcinoma cell line, showing a peak in c-met
mRNA expression at 4 h, which had fallen to basal levels by 16 h,
after stimulation with HGF/SF. Thus, a feedback loop may exist
whereby exposure ofPTECs to HGF/SF results in the induction of
c-met receptor expression, however it is presently unclear whether
c-met expression is specifically induced by HGF/SF, or whether
this represents a more general mitogenic response.
In summary, we have confirmed and extended previous studies
that have demonstrated an association between HGF/SF-induced
renal tubularmitogenesis and increased expression ofc-myc, c-fos,
c-met and VEGF. In addition, we have demonstrated that HGF/SF
increases elongin mRNA levels. No profound changes in VHL
mRNA levels were observed after HGF/SF, and current evidence
suggests that alterations in the VHL/elongin pathway function
associated with modulation of transcriptional elongation are
unlikely to be an important mediatorofHGF/SF-induced renal cell
mitogenesis.
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